| Naslov: | A case report and a literature review of Myeloid/Lymphoid Neoplasm with Eosinophilia and PCM1::JAK2 rearrangement representing as B-cell acute lymphoblastic leukemia B-ALL |
|---|
| Avtorji: | ID Čemažar, Luka (Avtor)
ID Šlajpah, Klara (Avtor)
ID Gredelj Šimec, Njetočka (Avtor)
ID Podgornik, Helena (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,14 MB)
MD5: 729CE64BF254952E276C94985BD5EEEC
 URL - Izvorni URL, za dostop obiščite https://link.springer.com/article/10.1007/s00277-026-06757-z
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions (MLN-eo-TK) represent a distinct and heterogeneous group of hematologic malignancies characterized by recurrent gene fusions involving tyrosine kinases, such as PDGFRA, PDGFRB, FGFR1, JAK2, FLT3, ETV::ABL1 and other partner genes/variants. Among these, gene rearrangements involving PCM1::JAK2 are rare and may present diagnostic challenges, particularly when manifesting as acute lymphoblastic leukemia (ALL). We describe a case of a patient who presented with B-cell acute lymphoblastic leukemia (B-ALL) with a JAK2 rearrangement. After the induction therapy, strong myeloid proliferation in bone marrow without evidence of residual lymphoblasts was observed and JAK2 rearrangement was recognized to be a consequence of translocation t(8;9)(p22;p24)] resulting in PCM1::JAK2 fusion. This finding indicated the presence of an underlying chronic myeloid/lymphoid neoplasm, meeting criteria for MLN-eo-TK. Following an inadequate response to standard chemotherapy, salvage regimens incorporating targeted agents (JAK2 and BCL-2 inhibitors) and allogeneic bone marrow transplantation were administered, all of which unfortunately resulted in short-lived clinical benefit. The case highlights the importance of distinguishing de novo lymphoid malignancies from MLN-eo-TK, especially when JAK2 rearrangements are detected. Recognition of the clonal myeloid component during or after lymphoid-directed therapy has important diagnostic and therapeutic implications, supporting the use of targeted JAK2 inhibition in addition to standard chemotherapy |
|---|
| Ključne besede: | Eosinophilia, MLN-eo-TK, PCM1:JAK2, B-ALL, acute lymphoblastic leukemia, therapy, lymphoid malignancies |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2026 |
|---|
| Št. strani: | str. 1-8 |
|---|
| Številčenje: | Vol. 105, issue 1 |
|---|
| PID: | 20.500.12556/DiRROS-25345  |
|---|
| UDK: | 616.1 |
|---|
| ISSN pri članku: | 1432-0584 |
|---|
| DOI: | 10.1007/s00277-026-06757-z |
|---|
| COBISS.SI-ID: | 264774147 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 15. 1. 2026;
|
|---|
| Datum objave v DiRROS: | 16.01.2026 |
|---|
| Število ogledov: | 272 |
|---|
| Število prenosov: | 158 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
